DDInter842 DDInter1376
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Denileukin diftitox
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Grepafloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Grepafloxacin {u} may lead to a major life threatening interaction when taken with {v} Insulin glargine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Denileukin diftitox
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Grepafloxacin may lead to a major life threatening interaction when taken with Encorafenib
Grepafloxacin may lead to a major life threatening interaction when taken with Insulin glargine